David A. Bristol
Direktor/Vorstandsmitglied bei HCF Enterprises, Inc.
Profil
David A.
Bristol is currently a Director at HCF Enterprises, Inc. and Sentinel Private Equity XVI Fund.
He was previously a Director at Nanospectra Biosciences, Inc. and a Geophysicist at Exxon Co. USA from 1988 to 1991.
Bristol received his undergraduate degree from Brown University and his graduate degree from The University of Texas at Austin.
Aktive Positionen von David A. Bristol
| Unternehmen | Position | Beginn |
|---|---|---|
| HCF Enterprises, Inc. | Direktor/Vorstandsmitglied | - |
| Sentinel Private Equity XVI Fund | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von David A. Bristol
| Unternehmen | Position | Ende |
|---|---|---|
| Exxon Co. USA | Corporate Officer/Principal | 02.01.1991 |
Nanospectra Biosciences, Inc.
 Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Direktor/Vorstandsmitglied | - |
Ausbildung von David A. Bristol
| Brown University | Undergraduate Degree |
| The University of Texas at Austin | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
| HCF Enterprises, Inc. | |
| Exxon Co. USA | |
| Sentinel Private Equity XVI Fund |
